## [Novartis statement regarding competition authority investigation into assertion of a patent](/news/media-releases/novartis-statement-regarding-competition-authority-investigation-assertion-patent "Novartis statement regarding competition authority investigation into assertion of a patent") Sep 15, 2022 - *Company confident to clarify legitimacy of its position and fully cooperating with authorities* **Basel, September 15, 2022** — Novartis today confirms that it has been contacted by the Swiss Competition Commission (COMCO) which has initiated an investigation, in collaboration with the European Commission, into the assertion of a patent in the broader field of dermatology treatments. In connection with this investigation, COMCO representatives visited the company headquarters in Basel. The opening of an investigation does not imply any finding of wrongdoing or any financial impact. Novartis is fully cooperating with the authorities and is confident to clarify the legitimacy of its position. As this is an ongoing investigation in its early stages, we will not comment further at this point in time. **Disclaimer** This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise. **About Novartis** Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at . Novartis is on Twitter. Sign up to follow @Novartis at [**https://twitter.com/novartisnews**](https://twitter.com/novartisnews) For Novartis multimedia content, please visit [**https://www.novartis.com/news/media-library**](https://www.novartis.com/news/media-library) For questions about the site or required registration, please contact [media.relations@novartis.com](mailto:media.relations@novartis.com "media.relations@novartis.com") \# # # Novartis Media Relations** E-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com "media.relations@novartis.com") Richard Jarvis Strategy & Financial Communications + 41 79 584 2326 (mobile) [richard.jarvis@novartis.com](mailto:richard.jarvis@novartis.com "richard.jarvis@novartis.com") Julie Masow Novartis US External Communications +1 862 579 8456 [julie.masow@novartis.com](mailto:julie.masow@novartis.com "julie.masow@novartis.com") Satoshi Sugimoto Communications Switzerland +41 79 619 2035 (mobile) [satoshi\_jean.sugimoto@novartis.com](mailto:satoshi_jean.sugimoto@novartis.com "satoshi_jean.sugimoto@novartis.com") **Novartis Investor Relations** Central investor relations line: +41 61 324 7944 E-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com "investor.relations@novartis.com") Central North America Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440 Nicole Zinsli-Somm +41 61 324 3809 Alina Levchuk +1 862 778 3372 Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912 ![](https://ml-eu.globenewswire.com/media/OTFmYmVhMGYtZDQzNC00NDE1LTllOTgtMTA4NmM4YjFkYmRiLTEwMTQwMjQ=/tiny/Novartis-Pharma-AG.png)